Literature DB >> 34536399

Neuropathology of progressive supranuclear palsy after treatment with tilavonemab.

Shunsuke Koga1, Dennis W Dickson1, Zbigniew K Wszolek2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34536399      PMCID： PMC9446286          DOI： 10.1016/S1474-4422(21)00283-0

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   59.935


× No keyword cloud information.
  6 in total

1.  Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies.

Authors:  T West; Y Hu; P B Verghese; R J Bateman; J B Braunstein; I Fogelman; K Budur; H Florian; N Mendonca; D M Holtzman
Journal:  J Prev Alzheimers Dis       Date:  2017

2.  Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo.

Authors:  Marc I Diamond; David M Holtzman; Kiran Yanamandra; Najla Kfoury; Hong Jiang; Thomas E Mahan; Shengmei Ma; Susan E Maloney; David F Wozniak
Journal:  Neuron       Date:  2013-09-26       Impact factor: 17.173

3.  Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial.

Authors:  Günter U Höglinger; Irene Litvan; Nuno Mendonca; Deli Wang; Hui Zheng; Beatrice Rendenbach-Mueller; Hoi-Kei Lon; Ziyi Jin; Nahome Fisseha; Kumar Budur; Michael Gold; Davis Ryman; Hana Florian
Journal:  Lancet Neurol       Date:  2021-03       Impact factor: 44.182

4.  Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.

Authors:  Günter U Höglinger; Gesine Respondek; Maria Stamelou; Carolin Kurz; Keith A Josephs; Anthony E Lang; Brit Mollenhauer; Ulrich Müller; Christer Nilsson; Jennifer L Whitwell; Thomas Arzberger; Elisabet Englund; Ellen Gelpi; Armin Giese; David J Irwin; Wassilios G Meissner; Alexander Pantelyat; Alex Rajput; John C van Swieten; Claire Troakes; Angelo Antonini; Kailash P Bhatia; Yvette Bordelon; Yaroslau Compta; Jean-Christophe Corvol; Carlo Colosimo; Dennis W Dickson; Richard Dodel; Leslie Ferguson; Murray Grossman; Jan Kassubek; Florian Krismer; Johannes Levin; Stefan Lorenzl; Huw R Morris; Peter Nestor; Wolfgang H Oertel; Werner Poewe; Gil Rabinovici; James B Rowe; Gerard D Schellenberg; Klaus Seppi; Thilo van Eimeren; Gregor K Wenning; Adam L Boxer; Lawrence I Golbe; Irene Litvan
Journal:  Mov Disord       Date:  2017-05-03       Impact factor: 10.338

5.  Tau immunotherapy is associated with glial responses in FTLD-tau.

Authors:  Boram Kim; Bailey Mikytuck; Eunran Suh; Garrett S Gibbons; Vivianna M Van Deerlin; Sanjeev N Vaishnavi; Meredith A Spindler; Lauren Massimo; Murray Grossman; John Q Trojanowski; David J Irwin; Edward B Lee
Journal:  Acta Neuropathol       Date:  2021-05-05       Impact factor: 17.088

Review 6.  Passive immunotherapies targeting Aβ and tau in Alzheimer's disease.

Authors:  Steven S Plotkin; Neil R Cashman
Journal:  Neurobiol Dis       Date:  2020-07-16       Impact factor: 7.046
  6 in total
  1 in total

Review 1.  Disease-Modifying Therapies for Alzheimer's Disease: More Questions than Answers.

Authors:  Todd E Golde
Journal:  Neurotherapeutics       Date:  2022-02-28       Impact factor: 7.620
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.